G D’Haens

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

Eric Van Cutsem, István Láng, G D’Haens et al. · Journal of Clinical Oncology · 2008 · 373 citations

Surgical Oncology, Cancer Management, Pathology +20

Point-of-care Intestinal Ultrasound in IBD Patients: Disease Management and Diagnostic Yield in a Real-world Cohort and Proposal of a Point-of-care Algorithm

Steven Bots, F de Voogd, Menno D. de Jong et al. · Journal of Crohn s and Colitis · 2021 · 53 citations · Full text

Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy?

Monique Elseviers, G D’Haens, Éric Lerebours et al. · Clinical Nephrology · 2004 · 47 citations

A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS results

David Cunningham, Rlc Wong, G D’Haens et al. · Journal of Clinical Oncology · 2008 · 29 citations

Immunology, Pathology, Oncology +16

The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri

Eric Van Cutsem, István Láng, G D’Haens et al. · Annals of Oncology · 2008 · 13 citations

Oncology, Clinical Therapeutic, Metronomic Therapy +7